Urine Prostaglandin-M(PGE-M) in Ovarian Cancer
- Determine the level of prostaglandin E_2 metabolite (PGE-M) in 24-hour urine samples
collected prior to surgery or chemotherapy from patients with ovarian cancer.
- Determine cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) expression by western
blot and immunohistochemistry (IHC) in ovarian tumor tissue samples and matched normal
ovarian tissue samples, if available, from these patients.
- Correlate urine PGE-M levels with corresponding tissue COX-1 and COX-2 levels in urine
and tissue samples from these patients.
OUTLINE: This is a pilot study.
Patients submit 24-hour urine specimens prior to surgery for evaluation of urinary levels of
prostaglandin E_2 metabolite (PGE-M).
Patients also undergo assessment of tissue obtained at the time of surgery, including
ovarian tumor tissue, normal surface ovarian epithelium tissue (if available), and fixed
tissue embedded in a paraffin block. Tissue samples are analyzed by western blot and IHC for
cyclooxygenase-1 and cyclooxygenase-2 expression.
Observational Model: Case-Only, Time Perspective: Prospective
Prostaglandin E2 metabolite (PGE-M) levels in 24-hour urine samples
Patients will be collect their urine for 24 hours before they undergo any surgery or chemotherapy. Researchers will measure the amount of PGE-M in the urine.
Pre-surgical or chemotherapeutic treatment, over a 24-hour duration
Marta Crispens, MD
Vanderbilt-Ingram Cancer Center
United States: Federal Government
VICC GYN 0648